![\"\"](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/07\/4000-logo.png\"){kind=logo}
<\/p>\n<\/p>\n
Saliva-Based Test Powered by Co-Diagnostics a Game Changer <\/p>\n
Maxim reiterate Buy with a price target of $30<\/em><\/strong><\/p>\n Earlier this week, Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented diagnostics testing platform, announced that its partner, Clinical Reference Laboratory (CRL), one of the largest testing providers in the country, had received Emergency Use Authorization (EUA) from the FDA for a self-collected, saliva-based PCR test for COVID-19. The test uses Co-Diagnostics probes and primers. CODX shares were up 28% on the news before seeing some profit taking on Tuesday.<\/p>\n CRL declared that the test has demonstrated 100% sensitivity\/specificity (higher than any other saliva-based molecular test for COVID-19) and can be processed within 24-48 hours, which is important considering that in many cases current tests are taking up to a week or more to return results. <\/p>\n That same day, the analyst from Maxim Group reiterated a Buy status and $30 PT on the Company’s stock. With COVID cases on the rise in the US and around the globe, and testing times increasing past the point of usefulness, interest in expanding testing capacity has increased markedly.<\/p>\n Some key highlights of the Maxim report include:<\/p>\n Disclosure: Co-Diagnostics Inc is a client of BDA International.<\/p>\n About BDA International, Inc.:<\/strong><\/p>\n BDA International is an independent global Investor Relations firm offering a wide range of IR-related analysis, research and advisory services. In particular, we provide and are compensated for service packages that include strategic action plans and investor\/market perception studies to help entities improve communication with customers and investors, and to increase their visibility. BDA International has received no direct compensation related to this release but its principles hold shares of client companies in our personal portfolios, including CODX. BDA International accepts sole responsibility for the content and distribution of the foregoing release, which does not contain any previously unpublished or non-public information. Parties interested in learning more about the relationship between BDA and CODX may do so via the contact information at the bottom of this release.<\/p>\n Investor Relations Contact: dost@bda-ir.com<\/p>\n Tags:<\/b> Mushtaq\u00a0Dost\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n
Mushtaq <\/strong>Dost<\/strong>
BDA International <\/strong>
www.bda-ir.com<\/p>\nSee Campaign: <\/strong>http:\/\/www.bda-ir.com<\/a>
Contact Information:<\/b>
MushtaqDost
\nBDA International
\nwww.bda-ir.com
\ndost@bda-ir.com<\/p>\n
<\/a>, Wire<\/a>, Disclosure Newswire<\/a>, United States<\/a>, English<\/a><\/p>\n<\/div>\n
\nContact Information:<\/h3>\n
\nBDA International\u00a0\u00a0\u00a0\u00a0
\nwww.bda-ir.com
\ndost@bda-ir.com<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"Saliva-Based Test Powered by Co-Diagnostics a Game Changer Maxim reiterate Buy with a price target of $30 Earlier this week, Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented diagnostics testing platform, announced that its partner, Clinical Reference Laboratory (CRL), one of the largest testing providers in the country, had received Emergency Use Authorization (EUA) from … Continue reading Saliva-Based Test Powered by Co-Diagnostics (NASDAQ:CODX) a Game Changer<\/span><\/a> Continue Reading